MAMMALIAN OLIGOPEPTIDE TRANSPORTERS - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 144

transfected cell line: establishing a correlation between expression and function. Mol.
Pharm. 1(2):136-144.
176. Bhardwaj, R.K., Herrera-Ruiz, D., Sinko, P.J., Gudmundsson, O.S., and Knipp, G.T.
(2005). Delineation of HPEPT1 meditated uptake and transport of substrates with varying
transporter affinities utilizing stably transfected HPEPT1/MDCK clones and Caco-2 cells.
J. Pharmacol. Exp. Ther. 314:1093-1100.
177. Beauchamp, L.M., Orr, G.F., de Miranda, P., Burnette, T., and Krenitsky, T.A. (1992).
Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. 3(3):157-164.
178. de Miranda, P., and Burnette, T.C. (1994). Metabolic fate and pharmacokinetics of the
acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. 22(1):55-
59.
179. Beutner, K.R. (1995). Valacyclovir: a review of its antiviral activity, pharmacokinetic
properties, and clinical efficacy. Antiviral Res. 28(4):281-290.
180. Crooks, R.J., and Murray, A. (1994). Valaciclovir: a review of a promising new antiherpes
agent. Antiviral Chem. Chemother. 5(1):31-37.
181. Balimane, P.V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F.H., Tsuji, A., and
Sinko, P.J. (1998). Direct evidence for peptide transporter (PepT1)-mediated uptake of a
nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250(2):246-251.
182. de Vrueh, R.L.A., Smith, P.L., and Lee, C.-P. (1998). Transport of L-valine-acyclovir via
the oligopeptide transporter in the human intestinal cell line, Caco-2. J. Pharmacol. Exp.
Ther. 286(3):1166-1170.
183. Ganapathy, M.E., Huang, W., Wang, H., Ganapathy, V., and Leibach, F.H. (1998). Vala-
cyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.
Biochem. Biophys. Res. Commun. 246(2):470-475.
184. Han, H.-K., de Vrueh, R.L.A., Rhie, J.K., Covitz, K.-M.Y., Smith, P.L., Lee, C.-P., Oh, D.-
M., Sadee, W., and Amidon, G.L. (1998). 5 -Amino acid esters of antiviral nucleosides,
acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm.
Res. 15(8):1154-1159.
185. Guo, A., Hu, P., Balimane, P.V., Leibach, F.H., and Sinko, P.J. (1999). Interactions of a
nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1)
expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 289(1):448-454.
186. Sinko, P.J., and Balimane, P.V. (1998). Carrier-mediated intestinal absorption of valacy-
clovir, the L-valyl ester prodrug of acyclovir. 1: Interactions with peptides, organic anions
and organic cations in rats. Biopharm. Drug Dispos. 19(4):209-217.
187. Sawada, K., Terada, T., Saito, H., Hashimoto, Y., and Inui, K.-I. (1999). Recognition
of L-Amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J.
Pharmacol. Exp. Ther. 291(2):705-709.
188. Landowski, C.P., Sun, D., Foster, D.R., Menon, S.S., Barnett, J.L., Welage, L.S., Ra-
machandran, C., and Amidon, G.L. (2003). Gene expression in the human intestine and
correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther.
306(2):778-786.
189. de Miranda, P., and Blum, M.R. (1983). Pharmacokinetics of acyclovir after intravenous
and oral administration. J. Antimicrob. Chemother. 12(suppl. B):29-37.
190. Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., and Posner, J. (1995). Absolute
bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, fol-
lowing oral administration to humans. Antimicrob. Agents Chemother. 39(12):2759-2764.